Table 1.
Case information and demographics
| Case | Age at death (years) | Sex | Education (years) | Testing obtained antemortem (months) | MMSE (/30) | Premorbid intelligence | PMIa | ApoE | CERAD | Brain weight | Braak staging | Non-Alzheimer pathology |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SA 1 | 87 | F | 12 | 1 | 29 | 133b | NA | ∈3/∈3 | 2 | 1240 | III | ARTAG, AGD |
| SA 2 | 90 | F | 18 | 1 | 29 | 135b | 4 | ∈3/∈3 | 0 | 990 | II–III | 1 remote lacunar infarct, left globus pallidus |
| SA 3 | 99 | F | 16 | 4 | 25 | 112b | 58 | ∈3/∈3 | 3 | 1020 | III | Multiple cortical microinfarcts (nonsignificant); 1 remote lacunar infarct, left putamen; ARTAG, AGD |
| SA 4 | 87 | F | 18 | 5 | 30 | 119b | 11 | ∈3/∈3 | 3 | 1090 | II–III | ARTAG |
| SA 5 | 81 | F | 18 | 8 | 30 | 106.76c | 9.5 | ∈3/∈3 | 1 | 1269 | 0-I | None |
| SA 6 | 90 | F | 14 | 8 | 29 | 110.81c | 5 | ∈2/∈3 | 0 | 1100 | II–III | PART (definite), Lewy body in dorsal motor nucleus of vagus (incidental), ARTAG |
| SA 7 | 95 | F | 18 | 12 | NA | 113.81c | 5 | NA | 0 | 1241 | 0 | None |
| NC 1 | 77 | F | NA | NA | NA | NA | 42 | NA | 1 | 1200 | III | NA |
| NC 2 | 89 | F | 16 | 21 | 29 | 138b | 6 | ∈2/∈3 | 2 | 1160 | III–IV | Vascular disease |
| NC 3 | 96 | F | 14 | 14 | NA | NA | 5 | NA | 0 | NA | IV | Mild ischemic changes |
| NC 4 | 88 | M | 12 | 11 | 28 | 100.81c | 12 | NA | 1 | 1250 | III–IV | Infarct, right temporal lobe |
| NC 5 | 82 | M | NA | NA | NA | NA | 24 | NA | 0 | NA | III | NA |
| NC 6 | 95 | F | 12 | 4 | 28 | 108.34c | 3.25 | ∈2/∈3 | 2 | 1096 | III | None |
Note: Cognitive measures were not identical for all participants and cognitive scores are provided as actual/total possible score. PMI, postmortem interval.
aARTAG, aging-related tau astrogliopathy; AGD, argyrophilic grain disease; PART, primary age-related tauopathy; NA, not available. Note, in cases noted as “None,” TDP-43 staining was not available.
bWAIS-III FSIQ.
cBarona Index premorbid intelligence estimate (M = 100; SD 15) (Barona et al. 1984); Braak staging followed published guidelines (Braak and Braak 1991, 1993); neuritic plaque score (0, 1, 2, or 3) was determined by the method of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (Mirra et al. 1991).